The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel
Gerd R Burmester(Charité - Universitätsmedizin Berlin), Herman Stoevelaar(Barnes-Jewish Hospital), Luigi M. Biasucci(Agostino Gemelli University Polyclinic), Carmelo Scarpignato(University of Parma), Stefan Lohmander(Lund University), Ignazio Olivieri(Ospedale Madonna Delle Grazie), Thomas M. MacDonald(Ninewells Hospital), Nele Van Den Noortgate(Ghent University Hospital), Ángel Lanas(Universidad de Zaragoza), Françis Berenbaum(Inserm), Matthias Hermann(Zurich Heart House), A. Bajkowski, Maxime Dougados(Inserm), Tony Mets(Universitair Ziekenhuis Brussel), C J Hawkey(NIHR Nottingham Digestive Diseases Biomedical Research Unit), E. Martín Mola(Hospital Universitario La Paz), Peter Dieleman(University of Antwerp)
Cited by 105
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
|Annals of the Rheumatic Diseases|2017|1.6k
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease
|Nature Genetics|2017|1.5k
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
|Annals of the Rheumatic Diseases|2013|1.4k